{"id":"generic-acyclovir","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"1-5","effect":"Nephrotoxicity (with IV administration)"},{"rate":"1-4","effect":"Neurotoxicity (confusion, hallucinations, tremors)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Acyclovir is a nucleoside analog that is phosphorylated by viral thymidine kinase to its active form, which then competitively inhibits viral DNA polymerase and causes chain termination during viral DNA synthesis. This selective mechanism exploits the virus's own enzymes, making it relatively selective for infected cells. It is effective against HSV-1, HSV-2, and VZV.","oneSentence":"Acyclovir inhibits viral DNA polymerase to prevent replication of herpes simplex virus and varicella-zoster virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:24.177Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Herpes simplex virus infection (HSV-1 and HSV-2)"},{"name":"Varicella-zoster virus infection (chickenpox and shingles)"},{"name":"Cytomegalovirus prophylaxis in immunocompromised patients"}]},"trialDetails":[{"nctId":"NCT06228430","phase":"PHASE1","title":"The Bioequivalence Study of Acyclovir 800 mg Tablet in Healthy Thai Volunteers Under Fasting Conditions","status":"UNKNOWN","sponsor":"International Bio service","startDate":"2024-02-12","conditions":"Healthy Volunteer","enrollment":40},{"nctId":"NCT03631316","phase":"NA","title":"Pharmacokinetic Parameters of Innovative Valganciclovir Versus Generic Valganciclovir","status":"COMPLETED","sponsor":"Luis Eduardo Morales Buenrostro","startDate":"2018-03-01","conditions":"Kidney Transplantation, Cytomegalovirus Infections, Pharmacokinetics","enrollment":8},{"nctId":"NCT00194519","phase":"PHASE3","title":"Herpes Simplex Virus Type 2 (HSV-2) Suppression to Prevent HIV Transmission","status":"COMPLETED","sponsor":"University of Washington","startDate":"2004-11","conditions":"HIV Infection, Herpes Simplex, Genital, Sexually Transmitted Diseases","enrollment":3408},{"nctId":"NCT02349828","phase":"PHASE2, PHASE3","title":"Antiviral Prophylaxis in a Burn Population","status":"WITHDRAWN","sponsor":"Southern Illinois University","startDate":"2015-09","conditions":"Herpes Simplex","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Generic acyclovir","genericName":"Generic acyclovir","companyName":"University of Washington","companyId":"university-of-washington","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Acyclovir inhibits viral DNA polymerase to prevent replication of herpes simplex virus and varicella-zoster virus. Used for Herpes simplex virus infection (HSV-1 and HSV-2), Varicella-zoster virus infection (chickenpox and shingles), Cytomegalovirus prophylaxis in immunocompromised patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}